Evidence map›Paper›PMID 42020715›Full record

ArticleCellular & molecular immunology2026

EZH2 and intracellular Ca

Ying Wang, Qingrong Huang, Yan Zhou, Robert Hooper, Ruqayyah Sanders-Braggs, Mimi Chen, Yuanyuan Tian, Tatiana Kent, Richard Pomerantz, Gennaro Clando and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ying Wang *Center for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA.
Qingrong Huang *Center for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA.
Yan ZhouBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA.
Robert HooperFels Institute and Department of Cancer Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Ruqayyah Sanders-BraggsCenter for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA.
Mimi ChenCenter for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA.
Yuanyuan TianCenter for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA.
Tatiana KentDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Richard PomerantzDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Gennaro ClandoCoriell Institute for Medical Research and Cooper Medical School at Rowan University, Camden, NJ, USA.
Woonbok ChungCoriell Institute for Medical Research and Cooper Medical School at Rowan University, Camden, NJ, USA.
Jean-Pierre J IssaCoriell Institute for Medical Research and Cooper Medical School at Rowan University, Camden, NJ, USA.ORCID 0000-0003-2258-5030
Jonathan SoboloffFels Institute and Department of Cancer Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.ORCID 0000-0001-5192-1297
Yi ZhangCenter for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, NJ, USA. yi.zhang@hmh-cdi.org.

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY · 2003 to 2023
$43.7M
Pathology CoreP50CA254897 · NCI · CORIELL INSTITUTE FOR MEDICAL RESEARCH · PI ISSA, JEAN-PIERRE J. · 2021 to 2025
$11.9M
Synthetic rescue of antigen-driven T cells and alloimmunityR01AI143256 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI SOBOLOFF, JONATHAN A, ZHANG, YI · 2019 to 2023
$2.9M
DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunityR01HL154757 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI ZHANG, YI · 2021 to 2024
$2.6M
ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejectionR01CA290808 · NCI · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Hai-Hui Xue, YI ZHANG · 2024 to 2026
$2.2M
Synthetic rescue of antigen-driven T cells and alloimmunityR56AI143256 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI SOBOLOFF, JONATHAN A, ZHANG, YI · 2019 to 2019
$353k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI143256NCI NIH HHS P50 CA100632NCI NIH HHS P50 CA254897NCI NIH HHS R01 CA290808NHLBI NIH HHS R01 HL154757NIAID NIH HHS R01 AI143256NIAID NIH HHS R56 AI143256U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA290808-01U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL154757
6 · The paper itself

Abstract

In graft-versus-host disease (GVHD), Ca

Indexed as

Calcium SignalingEnhancer of Zeste Homolog 2 ProteinGraft vs Host DiseaseReceptors, Chimeric AntigenT-LymphocytesAnimalsCalciumCell DifferentiationHumansInositol 1,4,5-Trisphosphate ReceptorsLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutStromal Interaction Molecule 1CalciumEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseInositol 1,4,5-Trisphosphate ReceptorsReceptors, Chimeric AntigenStim1 protein, mouseStromal Interaction Molecule 1Allogeneic HSCTEpigenetic regulationER calciumEZH2GVHDT cell

Identifiers

PMID42020715
PMCPMC13314966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.